This contract supports the PREVENT Cancer Preclinical Drug Development Program, which provides a structured approach to drug and vaccine development, from discovery to the clinic. This contract is a part of a multiple-award Indefinite Delivery Indefinite Quantity (IDIQ) pool to procure services related to Preclinical Efficacy and Intermediate Endpoint Biomarkers, which is also referred to as the Efficacy Pool.